M&A Will Accelerate In European Markets, Slow Down In U.S. – Schering CEO
This article was originally published in The Tan Sheet
Executive Summary
The Rx drug industry can expect to see much more merger activity among European companies, while consolidation in the U.S. essentially has tapered off, Schering-Plough CEO Fred Hassan said
You may also be interested in...
Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment
Merck KGaA Strengthens Its Biotech Presence With Serono Acquisition
Merck KGaA's acquisition of Serono, Europe's leading biotechnology company, will enhance the German drug maker's position in biologics with a portfolio generating over $2 bil. in sales in the segment
Novartis Resumes Merger Search; Talks Up Schering, Ups Stake In Roche
Novartis is resuming its search for a merger partner, CEO Daniel Vasella indicated during the company's 2003 results conference Jan. 22 in Zurich